Abstract
Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance.
MeSH terms
-
Animals
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / therapeutic use*
-
Clinical Trials as Topic / trends
-
Diarylquinolines
-
Drug Discovery / trends*
-
Humans
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / growth & development
-
Quinolines / chemistry
-
Quinolines / therapeutic use
-
Tuberculosis / drug therapy*
-
Tuberculosis / prevention & control
Substances
-
Antitubercular Agents
-
Diarylquinolines
-
Quinolines
-
bedaquiline